Mereo BioPharma Appoints Wills Hughes-Wilson
In her role, Ms. Hughes-Wilson will be responsible for leading and optimizing Mereo’s patient access and commercialization strategies, initially in a part-time role as the Company builds out its rare disease commercial infrastructure.
Dr. Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma commented “Ms. Hughes-Wilson brings in-depth market access and product launch expertise as well as a proven ability to develop and lead commercial planning efforts globally. With extensive experience in the rare and orphan disease areas, Ms. Hughes-Wilson will be instrumental as we advance our portfolio of rare product candidates through late-stage clinical development and towards commercialization. We are very pleased to welcome her and believe she will be a strong complement to our existing leadership team at Mereo.”